Invesco’s Bolt Biotherapeutics BOLT Stock Holding History

Invesco’s Portfolio BOLT Stock Details BOLT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-9,039	Closed	-$5.95M	–	3968
2021 Q1	$5.95M	Buy	+9,039	New	+$5.88M	﹤0.01%	2278

Other funds holding BOLT

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

PBPIA

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

NFGH

Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Invesco's BOLT Position: Q2 2021 in Review

Invesco sold out of Bolt Biotherapeutics (BOLT) in Q2 2021, closing a stake of 9,039 shares — an estimated $5.95M sold.

Invesco first reported a position in BOLT in Q1 2021 and held it in 1 quarter. The position peaked at $5.95M in Q1 2021. 61 funds tracked by Wall St. Rank hold BOLT as of Q2 2021.

Invesco reported no remaining Bolt Biotherapeutics position as of Q2 2021 after selling out during the quarter.
Invesco sold 9,039 Bolt Biotherapeutics shares in Q2 2021, an estimated $5.95M.
Invesco first reported a position in Bolt Biotherapeutics in Q1 2021 and held it in 1 quarter.
Invesco's Bolt Biotherapeutics position peaked at $5.95M in Q1 2021.
61 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q2 2021.

Based on Invesco's 13F filing for Q2 2021, filed 17 Aug 2021.